keyword
MENU ▼
Read by QxMD icon Read
search

Gemcitabine toxicity

keyword
https://www.readbyqxmd.com/read/27909037/safety-and-efficacy-of-stereotactic-body-radiation-therapy-combined-with-s-1-simultaneously-followed-by-sequential-s-1-as-an-initial-treatment-for-locally-advanced-pancreatic-cancer-silapanc-trial-study-design-and-rationale-of-a-phase-ii-clinical-trial
#1
Xiaofei Zhu, Xiaoping Ju, Fei Cao, Fang Fang, Shuiwang Qing, Yuxin Shen, Zhen Jia, Yangsen Cao, Huojun Zhang
INTRODUCTION: Upfront surgeries are not beneficial to most patients with pancreatic cancer. Therefore, more emphasis has been placed chemoradiotherapy in locally advanced pancreatic cancer recently. Gemcitabine-based regimens or FOLFIRINOX (a chemotherapy regimen including leucovorin, 5-FU, irinotecan, oxaliplatin) has been proven as a standard chemotherapy in pancreatic cancer. However, severe toxicities may prevent the completion of chemotherapy. S-1 has showed better objective response rates, similar overall survival rates and progression-free survival rates compared with gemcitabine, revealing that S-1 may be a potential candidate in treating pancreatic cancer, especially for patients refractory to gemcitabine...
December 1, 2016: BMJ Open
https://www.readbyqxmd.com/read/27901493/has-aidi-injection-the-attenuation-and-synergistic-efficacy-to-gemcitabine-and-cisplatin-in-non-small-cell-lung-cancer-a-meta-analysis-of-36-randomized-controlled-trials
#2
Zheng Xiao, Chengqiong Wang, Ling Chen, Xuemei Tang, Lianhong Li, Nana Li, Jing Li, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Gemcitabine and cisplatin is the first line chemotherapy for non-small cell lung cancer with high toxicity. Aidi injection is a cantharidin and astragalu-based Chinese herbs injection in China. Has Aidi injection attenuation and synergistic efficacy to GP in NSCLC? There is lack of strong evidence to prove it. To further reveal it, we systematically evaluated all related studies. We collected all studies about Aidi injection plus GP for NSCLC in Medline, Embase, Web of Science, CNKI, VIP, Wanfang Database, CBM, CCRCT, Chi-CTR, and US-clinical trials (established to June 2015)...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27897011/a-spatiotemporal-model-to-simulate-chemotherapy-regimens-for-heterogeneous-bladder-cancer-metastases-to-the-lung
#3
Kimberly R Kanigel Winner, James C Costello
Tumors are composed of heterogeneous populations of cells. Somatic genetic aberrations are one form of heterogeneity that allows clonal cells to adapt to chemotherapeutic stress, thus providing a path for resistance to arise. In silico modeling of tumors provides a platform for rapid, quantitative experiments to inexpensively study how compositional heterogeneity contributes to drug resistance. Accordingly, we have built a spatiotemporal model of a lung metastasis originating from a primary bladder tumor, incorporating in vivo drug concentrations of first-line chemotherapy, resistance data from bladder cancer cell lines, vascular density of lung metastases, and gains in resistance in cells that survive chemotherapy...
2016: Pacific Symposium on Biocomputing
https://www.readbyqxmd.com/read/27894196/development-and-characterization-of-folic-acid-conjugated-chitosan-nanoparticles-for-targeted-and-controlled-delivery-of-gemcitabinein-lung-cancer-therapeutics
#4
Fengqiang Wang, Yan Wang, Qingzhu Ma, Yuan Cao, Bo Yu
The present study was designed to investigate the tumor-targeting potential of gemcitabine (GEM)-loaded surface-tailored chitosan (CS)/poly (ethylene glycol) nanoparticles (FA-PEG-GEM-NPs). The nanoparticles encapsulated with GEM were prepared, characterized, and tethered with folic acid. The developed formulations were characterized with respect to particle size/poly-dispersity index, shape, and zeta potential analysis. The in vitro study shows the sustained drug-release kinetics during 48 h. The present result shows remarkable cytotoxicity rendered by GEM when delivered through FA-PEG-GEM-NPs formulation...
November 29, 2016: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/27889543/eus-guided-fine-needle-injection-of-gemcitabine-for-locally-advanced-and-metastatic-pancreatic-cancer
#5
Michael J Levy, Steven R Alberts, William R Bamlet, Patrick A Burch, Michael B Farnell, Ferga C Gleeson, Michael G Haddock, Michael L Kendrick, Ann L Oberg, Gloria M Petersen, Naoki Takahashi, Suresh T Chari
BACKGROUND & AIMS: Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy due to tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included ability to disease downstage leading to a R0 resection, and overall survival at 6 months, 12 months, and 5 years after therapy. PATIENTS AND METHODS: In a prospective study from a tertiary referral center, gemcitabine (38mg/ml) EUS-FNI was performed in PC patients before conventional therapy...
November 23, 2016: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27879189/gemcitabine-induced-hemolytic-uremic-syndrome-treated-with-eculizumab-or-plasmapheresis-two-case-reports%C3%A2
#6
María Esperanza López Rubio, Raquel Rodado Martínez, María Luisa Illescas, Encarnación Mateo Bosch, Mercedes Martínez Díaz, Lourdes de la Vara Inesta, Basilio Cabezuelo, María Elisa Morales Albuja, Eladio Lucas Guillén, Luisa Jimeno García
BACKGROUND: Drug-induced hemolytic-uremic syndrome (HUS) has shown good response to eculizumab (ECU). We present 2 cases of patients with gemcitabine-induced HUS (GEM-HUS), one of whom was treated with ECU and the other with conventional treatment. Patient 1: A 74-year-old male with resected adenocarcinoma of the pancreas started adjuvant treatment with GEM, but after 5 months GEM was discontinued due to acute kidney injury and severe hypertension. Laboratory analyses identified microangiopathic hemolytic anemia (MHA) and thrombocytopenia...
November 23, 2016: Clinical Nephrology
https://www.readbyqxmd.com/read/27873130/phase-i-clinical-and-pharmacokinetic-study-of-pm01183-a-tetrahydroisoquinoline-lurbinectedin-in-combination-with-gemcitabine-in-patients-with-advanced-solid-tumors
#7
Luis Paz-Ares, Martin Forster, Valentina Boni, Sergio Szyldergemajn, Jesús Corral, Samantha Turnbull, Antonio Cubillo, Carlos Fernandez Teruel, Iker López Calderero, Mariano Siguero, Patrick Bohan, Emiliano Calvo
Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in patients with advanced solid tumors. Methods Forty-five patients received escalating doses of PM01183/gemcitabine on Days 1 and 8 every 3 weeks (d1,8 q3wk) following a standard 3 + 3 design. Results PM01183 3.5 mg flat dose (FD)/gemcitabine 1000 mg/m(2) was the highest dose level tested. Dose-limiting toxicities (DLTs) were mostly hematological and resulted in the expansion of a lower dose level (PM01183 3...
November 21, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27858906/combination-of-125i-brachytherapy-and-chemotherapy-for-unresectable-recurrent-breast-cancer-a-retrospective-control-study
#8
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Recurrent breast cancer remains an incurable malignancy and cannot be removed by surgery in the majority of cases. This study aimed to explore the feasibility and efficacy of the combination of I brachytherapy and chemotherapy for the treatment of unresectable recurrent breast cancer. Patients with unresectable recurrent breast cancer treated between January 2011 and December 2014 with a combination of I brachytherapy and capecitabine or gemcitabine were evaluated and outcomes were compared with those of women treated with capecitabine or gemcitabine in conventional dose as a monotherapy...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27853997/a-phase-i-trial-investigating-pulsatile-erlotinib-in-combination-with-gemcitabine-and-oxaliplatin-in-advanced-biliary-tract-cancers
#9
Laura W Goff, Dana B Cardin, Jennifer G Whisenant, Liping Du, Tatsuki Koyama, Kimberly B Dahlman, Safia N Salaria, Ruth T Young, Kristen K Ciombor, Jill Gilbert, Stephen James Smith, Emily Chan, Jordan Berlin
Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with modest efficacy. Erlotinib given continuously may antagonize the action of chemotherapy against cycling tumor cells, but pulsatile dosing of erlotinib with chemotherapy may improve efficacy. The purpose of this study was to assess the safety of pulsatile erlotinib with GEMOX...
November 16, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27849649/a-multicenter-phase-ii-study-of-gemcitabine-capecitabine-and-bevacizumab-for-locally-advanced-or-metastatic-biliary-tract-cancer
#10
Renuka V Iyer, Venkata K Pokuri, Adrienne Groman, Wen W Ma, Usha Malhotra, Dan M Iancu, Catherine Grande, Tanios B Saab
OBJECTIVES: Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the safety/efficacy and potential biomarkers for bevacizumab in combination with gemcitabine-capecitabine in advanced BTCs. PATIENTS AND METHODS: Inoperable stage III/IV BTC patients in our prospective study were given 1000 mg/m of gemcitabine (on days 1, 8), 650 mg/m of capecitabine (on days 1 to 14), and 15 mg/kg of bevacizumab (on day 1) in 21-day cycles...
November 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27833144/therapeutic-efficacy-and-safety-of-s-1-based-combination-therapy-compare-with-s-1-monotherapy-following-gemcitabine-failure-in-pancreatic-cancer-a-meta-analysis
#11
Sinan Lu, Yuan Zhang, Xiaohu Zhou, Dongkai Zhou, Qifan Yang, Bingjie Ju, Xinyi Zhao, Zhenhua Hu, Haiyang Xie, Lin Zhou, Shusen Zheng, Weilin Wang
S-1 monotherapy is widely used following gemcitabine failure in pancreatic cancer, especially in East Asia. We performed a meta-analysis to determine whether S-1-based combination therapy had better efficacy and safety compared with S-1 monotherapy. We searched Pubmed, Web of Science, ClinicalTrials.gov, and Cochrane CENTRAL and subsequently included five trials with a total of 690 patients. The combined hazard ratio (HR) or risk ratio; the corresponding 95% confidence intervals of progression-free survival, overall survival, and overall response rate; and grade 3-4 adverse events were examined...
November 11, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27825639/drug-dose-per-kilogram-lean-body-mass-predicts-hematologic-toxicity-from-carboplatin-doublet-chemotherapy-in-advanced-non-small-cell-lung-cancer
#12
Bjørg Sjøblom, Jūratė Šaltytė Benth, Bjørn H Grønberg, Vickie E Baracos, Michael B Sawyer, Øystein Fløtten, Marianne J Hjermstad, Nina Aass, Marit Jordhøy
BACKGROUND: Variations in lean body mass (LBM) have been suggested to explain variations in toxicity from systemic cancer treatment. We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. PATIENTS AND METHODS: Patients received carboplatin (AUC [area under the plasma concentration vs...
October 5, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27807377/fixed-dose-rate-administration-of-gemcitabine-in-cancer-bearing-cats-a-pilot-study
#13
Crystal L Garnett, Teri A Guerrero, Carlos O Rodriguez
Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 μM. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2',2'-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography...
November 2016: Canadian Veterinary Journal. la Revue Vétérinaire Canadienne
https://www.readbyqxmd.com/read/27798825/biodistribution-of-self-assembling-polymer-gemcitabine-conjugate-after-systemic-administration-into-orthotopic-pancreatic-tumor-bearing-mice
#14
Krishna Kattel, Goutam Mondal, Feng Lin, Virender Kumar, Ram I Mahato
Therapeutic efficacy of gemcitabine (GEM) is severely limited due to its rapid metabolism by enzymatic deamination in vivo. We recently determined its therapeutic efficacy before (F-GEM) and after conjugation to poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate) (mPEG-b-PCC-g-GEM-g-DC, abbreviated as P-GEM) in subcutaneous and orthotopic pancreatic tumor bearing mice. In this study, pharmacokinetic (PK) parameters and biodistribution profiles of F-GEM and P-GEM were determined after intravenous injection into orthotopic pancreatic tumor bearing NSG mice...
October 31, 2016: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/27797249/impact-of-the-copper-transporter-protein-1-ctr1-polymorphism-on-adverse-events-among-advanced-nonsmall-cell-lung-cancer-patients-treated-with-a-carboplatin-gemcitabine-regimen
#15
Siriluk Kumpiro, Virote Sriuranpong, Nutthada Areepium
BACKGROUND: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm. PURPOSE: To establish both prevalence of CTR1 polymorphism and its impact on treatment related toxicity in Thai advanced NSCLC patients. MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27789470/topotecan-plus-carboplatin-versus-standard-therapy-with-paclitaxel-plus-carboplatin-pc-or-gemcitabine-plus-carboplatin-gc-or-pegylated-liposomal-doxorubicin-plus-carboplatin-pldc-a-randomized-phase-iii-trial-of-the-noggo-ago-study-group-ago-austria-and-geico
#16
J Sehouli, R Chekerov, A Reinthaller, R Richter, A Gonzalez-Martin, P Harter, H Woopen, E Petru, L C Hanker, E Keil, P Wimberger, P Klare, C Kurzeder, F Hilpert, A K Belau, A Zeimet, I Bover-Barcelo, U Canzler, S Mahner, W Meier
BACKGROUND: Randomized, phase III trial to evaluate safety and efficacy of topotecan and carboplatin (TC) compared with standard platinum-based combinations in platinum-sensitive recurrent ovarian cancer (ROC). PATIENTS AND METHODS: Patients were randomly assigned in a 1:1 ratio to the experimental TC arm (topotecan 0.75 mg/m(2)/ days 1-3 and carboplatin AUC 5 on day 3 every 3 weeks) or to one of the standard regimes [(PC) paclitaxel plus carboplatin; (GC) gemcitabine plus carboplatin; (PLDC) pegylated liposomal doxorubicin and carboplatin] which could be chosen by individual preference but before randomization...
October 26, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27769210/efficacy-and-safety-profile-of-nab-paclitaxel-plus-gemcitabine-in-patients-with-metastatic-pancreatic-cancer-treated-to-disease-progression-a-subanalysis-from-a-phase-3-trial-mpact
#17
Arndt Vogel, Josefine Römmler-Zehrer, Jack Shiansong Li, Desmond McGovern, Alfredo Romano, Michael Stahl
BACKGROUND: The phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall survival, the primary endpoint. In the MPACT trial, patients were treated until progressive disease (PD) or unacceptable toxicity. The current exploratory analysis investigated outcomes of patients from the MPACT trial who were treated until PD, in order to understand how to maximize treatment benefit from nab-P + Gem...
October 21, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27765912/an-assessment-of-the-benefit-risk-balance-of-folfirinox-in-metastatic-pancreatic-adenocarcinoma
#18
Julien Péron, Pascal Roy, Thierry Conroy, Françoise Desseigne, Marc Ychou, Sophie Gourgou-Bourgade, Trevor Stanbury, Laurent Roche, Brice Ozenne, Marc Buyse
BACKGROUND: We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma. METHODS: We used generalized pairwise comparisons. This statistical method permits the simultaneous analysis of several prioritized outcome measures. The first priority outcome was survival time (OS). Differences in OS that exceeded two months were considered clinically relevant. The second priority outcome was toxicity...
October 19, 2016: Oncotarget
https://www.readbyqxmd.com/read/27765756/safety-and-efficacy-of-nivolumab-and-standard-chemotherapy-drug-combination-in-patients-with-advanced-non-small-cell-lung-cancer-a-four-arms-phase-ib-study
#19
S Kanda, K Goto, H Shiraishi, E Kubo, A Tanaka, H Utsumi, K Sunami, S Kitazono, H Mizugaki, H Horinouchi, Y Fujiwara, H Nokihara, N Yamamoto, H Hozumi, T Tamura
BACKGROUND: The human IgG4 monoclonal antibody nivolumab targets programmed cell death-1 (PD-1) and promotes antitumor response by blocking the interaction of PD-1 with its ligands. This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients who had stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC were eligible...
October 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27765363/coadministration-of-a-gloriosa-superba-extract-improves-the-in-vivo-antitumoural-activity-of-gemcitabine-in-a-murine-pancreatic-tumour-model
#20
Rica Capistrano I, Christel Vangestel, Hanne Vanpachtenbeke, Erik Fransen, Steven Staelens, Sandra Apers, Luc Pieters
BACKGROUND: Gloriosa superba L. (glory lily, Colchicaceae) contains colchicine, and related alkaloids such as 3-O-demethylcolchicine and its glycoside colchicoside. Previously the in vivo efficacy of a crude extract and a colchicine-poor / colchicoside-rich extract of G. superba seeds was shown in a murine model of pancreatic adenocarcinoma. HYPOTHESIS/PURPOSE: The efficacy can be improved without obvious signs of toxicity by increasing the treatment dose; the efficacy of gemcitabine can be improved by coadministration of a Gloriosa superba extract...
November 15, 2016: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
keyword
keyword
103368
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"